The Mounjaro vs Ozempic comparison is one of the most searched by those considering GLP-1 agonist treatments for weight loss and diabetes control. Both are revolutionary medications, but have important differences that may influence your choice.
What Are Mounjaro and Ozempic
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both injectable GLP-1 receptor agonists used for type 2 diabetes treatment and, increasingly, for weight loss. However, they have slightly different mechanisms of action.
Acompanhe o nível estimado de cada dose e saiba a hora certa de aplicar.
Ver no appMain Difference: Mono vs Dual
Ozempic: GLP-1 Monotherapy
Ozempic acts only on the GLP-1 receptor, mimicking the intestinal hormone that controls appetite and glucose. It's the classic, well-established choice in the market.
Mounjaro: Dual GIP/GLP-1 Therapy
Mounjaro goes further, acting on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual approach may provide superior results in terms of weight loss.
Mounjaro vs Ozempic: Compared Efficacy
Clinical studies show Mounjaro may provide greater weight loss than Ozempic:
- Mounjaro (tirzepatide): up to 22.5% body weight loss
- Ozempic (semaglutide): up to 15-20% body weight loss
However, individual response varies and both are highly effective for weight loss.
Side Effects: Mounjaro vs Ozempic
Both share similar side effects:
- Nausea and vomiting
- Gastrointestinal disturbances
- Fatigue
Mounjaro may have a slightly higher rate of gastrointestinal side effects due to its greater potency.
